

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5523580

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WENSHENG NIE	05/13/2019
TIMOTHY SWEENEY	05/14/2019
RECEIVING PARTY DATA	
Name:	INFLAMMATIX, INC.
Street Address:	863 MITTEN ROAD
Internal Address:	SUITE 104
City:	BURLINGAME
State/Country:	CALIFORNIA
Postal Code:	94010
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16410161
CORRESPONDENCE DATA	
Fax Number:	(415)576-0300
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	415-576-0200
Email:	jdallara@kilpatricktownsend.com
Correspondent Name:	PETER FOLLETTE
Address Line 1:	TWO EMBARCADERO CENTER
Address Line 2:	19TH FLOOR
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111-3834
ATTORNEY DOCKET NUMBER:	103604-1138699-000210US
NAME OF SUBMITTER:	JO ANN HONCIK DALLARA
SIGNATURE:	/Jo Ann Honcik Dallara/
DATE SIGNED:	05/15/2019
Total Attachments: 3	
source=Assignment1138699#page1.tif	
source=Assignment1138699#page2.tif	
source=Assignment1138699#page3.tif	

ASSIGNMENT
(Patent Application)

We [I], the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“DNA SEQUENCES RELATED TO DIAGNOSIS AND TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,”

the specification identified by U.S. Application No. 16/410,161, filed on May 13, 2019.

We [I]:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Inflammatrix, Inc., a corporation of the State of Delaware having a principal place of business at 863 Mitten Road, Suite 104, Burlingame, CA 94010 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee’s own use.

DNA SEQUENCES RELATED TO DIAGNOSIS AND TREATMENT OF SYSTEMIC
INFLAMMATORY RESPONSE SYNDROME


Attorney Docket No. 103604-1138699-000210US

Page 2 of 3


2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us [me], as well as our [my] heirs, legal representatives, and assigns.
5. Promise and affirm that we [I] have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our [my] signatures [signature].

Dated: 05/13/2019


Wensheng Nie


Dated: May 14 2019


Timothy Sweeney

Digitally signed by Timothy Sweeney
Date: 2019.05.14 09:34:32 -07'00'
Adobe Acrobat version:
2019.010.20099

DEED OF ACCEPTANCE

I (we) Inflammatrix, Inc., with offices at 863 Mitten Road, Suite 104,
Burlingame, CA 94010, USA declare that I (we) accept the rights given in the attached
Assignment.

By:  Digitally signed by Timothy
Sweeney
Date: 2019.05.14 09:34:48 -07'00'
Adobe Acrobat version:
2019.010.20099

NAME: Timothy Sweeney

TITLE: Chief Executive Officer